These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19220251)

  • 1. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
    Morote J; Ramirez C; Gómez E; Planas J; Raventós CX; de Torres IM; Catalán R
    BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
    Morote J; Planas J; Ramirez C; Gómez E; Raventós CX; Placer J; Catalán R; de Torres IM
    BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.
    Teloken C; Da Ros CT; Caraver F; Weber FA; Cavalheiro AP; Graziottin TM
    J Urol; 2005 Dec; 174(6):2178-80. PubMed ID: 16280759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
    Park HK; Hong SK; Byun SS; Lee SE
    Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
    Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
    J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
    Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
    Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between prostate cancer and serum testosterone levels.
    Zhang PL; Rosen S; Veeramachaneni R; Kao J; DeWolf WC; Bubley G
    Prostate; 2002 Nov; 53(3):179-82. PubMed ID: 12386917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.
    Rhoden EL; Riedner CE; Morgentaler A
    J Urol; 2008 May; 179(5):1741-4. PubMed ID: 18343420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.
    Kravchick S; Peled R; Dorfman D; Agulansky L; Ben-Dor D; Cytron S
    Urology; 2005 Sep; 66(3):542-6. PubMed ID: 16140074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
    Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
    J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
    Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
    Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.